This study compared the GPS of patients at diagnosis and at the first-line treatment failure of osimertinib, revealing an acquired MET amplification rate of 41.9% (13/31) in tissue samples, which was 15.6% (17/109) in plasma samples in the FLAURA study.14 The frequency of acquired TP53 mutations was 35.5% (11/31) in this study, whereas it was 3% in a prior report.15 The discrepancy likely stems from three reasons: incomplete baseline NGS data in routine clinical practice, divergence between diagnostic and treatment failure of osimertinib by NGS assays, and tumor heterogeneity. Here, TP53 is linked to neoplasm.